产品名称	IM9人外周血B淋巴瘤细胞
货号	ZQ1101
产品介绍	1967年从一名患有多发性骨髓瘤的妇女的骨髓中建立；文献中描述了合成IgG并具有胰岛素和降钙素受体的细胞；细胞表达BCL2 mRNA细胞似乎更像“EBV+ B淋巴母细胞”而不是骨髓瘤衍生细胞,通过PCR分析，该细胞系对EBV（HHV-4）呈阳性。此外，在用佛波酯/丁酸钠刺激细胞后，通过蛋白质印迹检测立即早期蛋白BZLF-1的表达。该感染被归类为与可能产生活性病毒相关的潜在裂解性感染。
种属	人
性别/年龄	女/***
组织	外周血
疾病	多发性骨髓瘤
细胞类型	肿瘤细胞
形态学	B淋巴母细胞
生长方式	悬浮
倍增时间	大约23~45小时
培养基和添加剂	RPMI-1640（品牌：中乔新舟 货号：ZQ-200）+10%胎牛血清（中乔新舟  货号：ZQ500-A）+1%P/S（中乔新舟  货号：CSP006）
推荐完全培养基货号	ZM1101
生物安全等级	BSL-1
培养条件	95%空气，5%二氧化碳；37℃
STR位点信息	Amelogenin ：X CSF1PO ：10,11 D2S1338 ：24,26 D3S1358： 14,18 D5S818： 13 D7S820： 11,12 D8S1179： 12,13 D13S317： 9,11 D16S539： 9,13 D18S51： 14,17 D19S433： 13,14 D21S11： 30,30.2 FGA ：20,23 Penta D： 9,11 Penta E： 13,15 TH01： 6,9.3 TPOX： 11 vWA ：14,17
抗原表达/受体表达	***
基因表达	***
保藏机构	ATCC; CCL-159 BCRC; 60115 CLS; 302151
供应限制	仅供科研使用

PubMed=2836165; DOI=10.1210/endo-122-6-2508
DiMattia G.E., Gellersen B., Bohnet H.G., Friesen H.G.
A human B-lymphoblastoid cell line produces prolactin.
Endocrinology 122:2508-2517(1988)

PubMed=1366653; DOI=10.1007/BF00365265
Bonhoff A., Gellersen B., Held K.R., Bohnet H.G.
Clonal derivatives of a human B-lymphoblastoid cell line producing prolactin -- a cytogenetic characterization.
Cytotechnology 3:43-50(1990)

CLPUB00447

Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

PubMed=8139288; DOI=10.1016/0145-2126(94)90118-x
Sato S., Honma Y., Hozumi M., Hayashi Y., Matsuo Y., Shibata K., Omura S., Hino K.-i., Tomoyasu S., Tsuruoka N.
Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
Leuk. Res. 18:221-228(1994)

PubMed=7579375; DOI=10.1182/blood.V86.10.4001.bloodjournal86104001
Pellat-Deceunynck C., Amiot M., Bataille R., Van Riet I., Van Camp B., Omede P., Boccadoro M.
Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after.
Blood 86:4001-4002(1995)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=10516762; DOI=10.1038/sj.leu.2401510
Drexler H.G., Dirks W.G., MacLeod R.A.F.
False human hematopoietic cell lines: cross-contaminations and misinterpretations.
Leukemia 13:1601-1607(1999)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29892436; DOI=10.1098/rsos.172472
Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.
Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.
R. Soc. Open Sci. 5:172472-172472(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)